New drug combo targets tough pancreatic cancer in early trial

NCT ID NCT06059001

Ongoing Disease control Sponsor: Peptomyc S.L. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called OMO-103, which blocks a cancer-driving protein called MYC, combined with standard chemotherapy in 26 people with metastatic pancreatic cancer who have not had prior treatment for advanced disease. The main goals are to check safety and how well the body handles the drug, while also looking for signs that tumors shrink or stop growing. This is not a cure, but aims to better control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm Neoplasm Metastasis pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC CANCER

Contacts and locations

Locations

Hospital Gregorio Marañon

Madrid, Madrid, 28007, Spain
Hospital Miguel Servet

Zaragoza, Zaragoza, 5009, Spain
Hospital Regional Universitario de Málaga

Málaga, Spain, 29010, Spain
Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, 39008, Spain
Hospital Vall d´Hebrón

Barcelona, Barcelona, 08035, Spain
ICO Hopsitalet

L'Hospitalet de Llobregat, Barcelona, 08908, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.